TREE NEWS reports: Genmab’s American depositary receipts rose 9.3% after the company reported positive Phase 3 study data. The Danish biotech’s shares climbed on the trial results, which the company said were favorable. No further details on the study or its implications were disclosed in the available material.
Genmab ADR Jumps 9.3% on Positive Phase 3 Data
AI take
The move reflects how sharply binary clinical readouts can reprice a biotech, with the ADR absorbing the reaction rather than the Copenhagen listing. What stands out is the absence of disclosed detail — efficacy endpoints, safety profile and the specific indication are all missing, so the market is trading on the headline rather than the data. Whether the full results, once available, support this re-rating is the open question, and the gap between headline and substance is worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
51m ago
SK Hynix Scraps Solidigm US IPO, May Benefit Micron and SanDisk: Analyst
2h ago
Italian bank index falls 5.9% for the week
2h ago
STOXX 600 closes down 0.57% at 634.10, weekly loss about 1.6%
2h ago
Bristol Myers Squibb Discloses Patient Death in Early CAR-T Trial
2h ago
Reliance’s Jio Platforms India IPO Draws Record 13.8 Million Bids
2h ago
Jio Platforms IPO draws $77B in bids, India’s most-subscribed offering